Metastatic Neuroendocrine
10.1200/JCO.2019.37.15_SUPPL.E15693

Role of resection of the primary in metastatic well/intermediate-differentiated neuroendocrine tumor (NET).


Metastatic Neuroendocrine
10.1080/10428194.2019.1612060

Inversion 16 (inv(16)) acute myeloid leukemia (AML) following treatment with radiation, capecitabine, and temozolomide in a patient with metastatic neuroendocrine tumor (NET)


Metastatic Neuroendocrine
10.1200/JCO.2019.37.15_SUPPL.4102

A phase I study of oncolytic immunotherapy of metastatic neuroendocrine tumors using intralesional rose bengal disodium: Cohort 1 results.


Metastatic Neuroendocrine
10.1159/000503901

Elderly Patients with Metastatic Neuroendocrine Tumors Are Undertreated and Have Shorter Survival: The LyREMeNET Study


Metastatic Neuroendocrine
10.1007/s12032-019-1266-0

First experience of durable cytoreduction in chronic lymphoid leukemia with 177Lu-DOTATATE


Metastatic Neuroendocrine
10.7759/cureus.6075

Severe Hypercalcemia as the Initial Presentation of a Neuroendocrine Carcinoma of Unknown Primary Site: A Case Report


Metastatic Neuroendocrine
10.1634/theoncologist.2018-0675

Meta-Analysis of Randomized Clinical Trials Comparing Active Treatment with Placebo in Metastatic Neuroendocrine Tumors.


Metastatic Neuroendocrine
10.1177/0300891619832263

A rare testicular tumor: primary carcinoid tumor


Metastatic Neuroendocrine
10.1080/14740338.2019.1559294

The safety of lanreotide for neuroendocrine tumor


Metastatic Neuroendocrine
10.1016/J.EHPC.2019.200319

Metastatic well-differentiated neuroendocrine tumor in the breast: A case report and literature review


Metastatic Neuroendocrine
10.1016/j.idcr.2019.e00596

Metastatic malignancy masquerading as neurocysticercosis


Metastatic Neuroendocrine
10.1097/RLU.0000000000002646

Efficacy of 177Lu Peptide Receptor Radionuclide Therapy for the Treatment of Neuroendocrine Tumors


Metastatic Neuroendocrine
10.1530/ERC-18-0424

Peptide receptor radionuclide therapy in gastroenteropancreatic NEN G3: a multicenter cohort study.


Metastatic Neuroendocrine
10.1007/s00259-019-04530-1

Dose escalation of an Evans blue–modified radiolabeled somatostatin analog 177Lu-DOTA-EB-TATE in the treatment of metastatic neuroendocrine tumors


Metastatic Neuroendocrine
10.1016/j.radonc.2019.09.003

68Ga-DOTATATE PET/CT parameters predict response to peptide receptor radionuclide therapy in neuroendocrine tumours.


Metastatic Neuroendocrine
10.1210/JS.2019-SAT-LB060

SAT-LB060 Clinical Presentation and Management of Primary Ovarian Carcinoids in Multiple Endocrine Neoplasia Type 1


Metastatic Neuroendocrine
10.1210/jc.2019-00082

Clinical Features of Multiple Endocrine Neoplasia Type 4: Novel Pathogenic Variant and Review of Published Cases


Metastatic Neuroendocrine
10.3390/ijms20123049

Somatostatin Analogues in the Treatment of Neuroendocrine Tumors: Past, Present and Future


Metastatic Neuroendocrine
10.1097/rlu.0000000000002802

Gastric Mucosal Hypertrophy Masquerading as Metastasis From Neuroendocrine Tumor of the Pancreas Detected on 68Ga-DOTANOC PET/CT.


Metastatic Neuroendocrine
10.25179/tjem.2018-62733

Critical Role of Ga–68 DOTATATE PET-CT in a Patient with Neuroendocrine Tumor and Second Primary Cancer


Metastatic Neuroendocrine
10.1200/jgo.2019.5.suppl.81

Development of hematologic toxicity with sequential treatment of Y90 followed by PRRT in five patients at single institution with metastatic neuroendocrine patients.


Metastatic Neuroendocrine
10.1007/s13139-019-00579-w

Eruption of Metastatic Paraganglioma After Successful Therapy with 177Lu/90Y-DOTATOC and 177Lu-DOTATATE


Metastatic Neuroendocrine
10.4172/2155-9619.1000395

Integrating Early Rapid Post-Peptide Receptor Radionuclide Therapy Quality Assurance Scan into the Outpatient Setting.


Metastatic Neuroendocrine
10.1200/JCO.2019.37.15_SUPPL.E15687

Evaluation of Ki67 and other predictors of survival in metastatic neuroendocrine tumor (NET) to the liver treated with Y90 radioembolization.


Metastatic Neuroendocrine
10.1016/J.HLC.2019.05.183

Early Outcomes of Surgery for Carcinoid Heart Disease.


Metastatic Neuroendocrine
10.7326/M19-0361

Would You Refer This Patient With Cancer to a Palliative Care Specialist?


Metastatic Neuroendocrine
10.1159/000496388

Carcinoid Syndrome-Induced Scleroderma-Like Disease


Metastatic Neuroendocrine
10.1097/SLA.0000000000003237

Prior Resection of the Primary Tumor Prolongs Survival After Peptide Receptor Radionuclide Therapy of Advanced Neuroendocrine Neoplasms.


Metastatic Neuroendocrine
10.1016/J.SURONC.2019.05.002

Local treatment of liver metastases by administration of 177Lu-octreotate via isolated hepatic perfusion - A preclinical simulation of a novel treatment strategy.


Metastatic Neuroendocrine
10.3747/co.26.4135

Prognostic value of inflammation-based markers in advanced or metastatic neuroendocrine tumours.


Metastatic Neuroendocrine
10.1016/j.anndiagpath.2018.11.002

Somatostatin receptor SSTR2A and SSTR5 expression in neuroendocrine breast cancer.


Metastatic Neuroendocrine
10.37174/2587-7593-2019-2-3-21-30

МРТ-оценка эффективности трансартериальной химиоэмболизации печени у пациентов с метастазами нейроэндокринных опухолей


Metastatic Neuroendocrine
10.21037/jtd.2019.08.71

Hedinger syndrome: first experience and two-year follow-up in patients with carcinoid heart disease.


Metastatic Neuroendocrine
10.1016/j.radcr.2019.02.022

A case of pseudocystic liver metastases from an atypical lung carcinoid tumor


Metastatic Neuroendocrine
10.12691/ajmcr-7-7-4

Tumor Lysis Syndrome after Hepatic Artery Embolization in a Patient with Neuroendocrine Tumor of Unknown Primary


Metastatic Neuroendocrine
10.1186/s40658-019-0243-1

Radiation precautions for inpatient and outpatient 177Lu-DOTATATE peptide receptor radionuclide therapy of neuroendocrine tumours


Metastatic Neuroendocrine
10.1111/tbj.13448

Bilateral breast metastasis from pancreatic neuroendocrine tumor: A diagnostic challenge


Metastatic Neuroendocrine
10.1097/MPA.0000000000001271

Periprocedural Management of Patients Undergoing Liver Resection or Embolotherapy for Neuroendocrine Tumor Metastases


Metastatic Neuroendocrine
10.1136/bcr-2018-227068

Hypokalaemic metabolic alkalosis, hypertension and diabetes: what is the link


Metastatic Neuroendocrine
10.1186/s12883-019-1310-x

Neuroendocrine carcinoma of the colon presenting as acute meningitis


Metastatic Neuroendocrine
10.1210/JS.2019-SAT-585

SAT-585 Presence of Metastatic Medullary Thyroid Cancer without a Distinct Thyroid Nodule: A Diagnostic Challenge


Metastatic Neuroendocrine
10.1093/annonc/mdz256

177Lu-DOTATATE plus 166Ho-radioembolization in patients with neuroendocrine tumours: A single center, prospective, interventional, non-comparative, open label, phase II study (HEPAR PLUS study)


Metastatic Neuroendocrine
10.2967/jnumed.118.213496

New Developments in Peptide Receptor Radionuclide Therapy


Metastatic Neuroendocrine
10.1097/MD.0000000000014989

A case report on metastatic ileal neuroendocrine neoplasm to the breast masquerading as primary breast cancer


Metastatic Neuroendocrine
10.1210/JS.2019-SUN-LB068

SUN-LB068 Ectopic Cushing Syndrome Due to a Metastatic Neuroendocrine Tumor Treated with Metyrapone


Metastatic Neuroendocrine
10.1007/s00259-019-04389-2

Characteristics and outcomes of therapy-related myeloid neoplasms after peptide receptor radionuclide/chemoradionuclide therapy (PRRT/PRCRT) for metastatic neuroendocrine neoplasia: a single-institution series


Metastatic Neuroendocrine
10.1007/s40336-019-00327-2

Peptide receptor radionuclide therapy after NETTER-1 clinical trial: what should not be left behind


Metastatic Neuroendocrine
10.1093/ons/opz232

Brainstem Tumor Resection via Occipital Interhemispheric Transtentorial Infracollicular Approach: 2-Dimensional Operative Video.


Metastatic Neuroendocrine
10.1089/ars.2018.7517

Protection of Kidney Function with Human Antioxidation Protein α1-Microglobulin in a Mouse 177Lu-DOTATATE Radiation Therapy Model


Metastatic Neuroendocrine
10.5603/EP.a2019.0024

Neuroendocrine tumour metastasis to the orbit- case report.


Metastatic Neuroendocrine
10.1210/jc.2018-01214

The Inflammation-Based Index Can Predict Response and Improve Patient Selection in NETs Treated With PRRT: A Pilot Study


Highly Related Keywords of Metastatic Neuroendocrine